"Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients ...
Becton, Dickinson and Company BDX, popularly known as BD, recently announced the global commercial launch of BD Research Cloud 7.0, marking another step forward in its AI-driven life sciences strategy ...
Over the past decade, flow cytometry has undergone transformative advancements, notably with the adoption of spectral flow cytometry and the emergence of next-generation imaging cytometers. These ...
Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
BD has found a new home for its biosciences and diagnostics divisions at the lab equipment maker Waters Corporation, through a transaction valued at $17.5 billion that ranks it as one of the largest ...
Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...
Flow cytometry has become a key analytical technique in clinical trials. Through its multiparametric analysis, single-cell resolution, and high-throughput evaluation capabilities, flow cytometry can ...
FRANKLIN LAKES, N.J. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)), a leading global medical technology company, and Biosero, a developer of laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results